share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  12/21 06:05

Moomoo AI 已提取核心信息

Conduit Pharmaceuticals received a delisting notice from Nasdaq on December 17, 2024, due to its stock price closing below $0.10 for ten consecutive trading days. The company plans to request a hearing to present its compliance plan and seek an extension. Delisting action is stayed pending the hearing outcome.At the annual meeting on December 18, shareholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-100, to be determined by the Board. This move aims to regain compliance with Nasdaq's listing requirements. Additionally, Simon Fry's appointment as director became effective, resolving a previous audit committee compliance issue.Shareholders also ratified Marcum LLP as the independent auditor for 2024 and re-elected six directors. The company's common stock and warrants continue trading on Nasdaq under "CDT" and "CDTTW" symbols, subject to ongoing listing deficiencies and the hearing process outcome.
Conduit Pharmaceuticals received a delisting notice from Nasdaq on December 17, 2024, due to its stock price closing below $0.10 for ten consecutive trading days. The company plans to request a hearing to present its compliance plan and seek an extension. Delisting action is stayed pending the hearing outcome.At the annual meeting on December 18, shareholders approved a reverse stock split at a ratio between 1-for-10 and 1-for-100, to be determined by the Board. This move aims to regain compliance with Nasdaq's listing requirements. Additionally, Simon Fry's appointment as director became effective, resolving a previous audit committee compliance issue.Shareholders also ratified Marcum LLP as the independent auditor for 2024 and re-elected six directors. The company's common stock and warrants continue trading on Nasdaq under "CDT" and "CDTTW" symbols, subject to ongoing listing deficiencies and the hearing process outcome.
Conduit Pharmaceuticals于2024年12月17日收到了纳斯达克的退市通知,因为其股价连续十个交易日收盘低于0.10美元。该公司计划申请听证会以呈现其合规计划并寻求延期。退市行动在听证结果出来之前暂时搁置。在12月18日的年度会议上,股东批准了一项1对10至1对100的反向拆股,具体比例由董事会决定。这一举措旨在重新获得遵守纳斯达克上市要求的资格。此外,西蒙·弗莱的董事任命生效,解决了之前审计委员会的合规问题。股东还确认了Marcum LLP为2024年的独立审计师,并重新选举了六位董事。公司的普通股和Warrants继续在纳斯达克以“CDT”和“CDTTW”符号交易,但面临持续的上市缺陷和听证程序的结果。
Conduit Pharmaceuticals于2024年12月17日收到了纳斯达克的退市通知,因为其股价连续十个交易日收盘低于0.10美元。该公司计划申请听证会以呈现其合规计划并寻求延期。退市行动在听证结果出来之前暂时搁置。在12月18日的年度会议上,股东批准了一项1对10至1对100的反向拆股,具体比例由董事会决定。这一举措旨在重新获得遵守纳斯达克上市要求的资格。此外,西蒙·弗莱的董事任命生效,解决了之前审计委员会的合规问题。股东还确认了Marcum LLP为2024年的独立审计师,并重新选举了六位董事。公司的普通股和Warrants继续在纳斯达克以“CDT”和“CDTTW”符号交易,但面临持续的上市缺陷和听证程序的结果。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息